Email Artikel ini REVIEW ARTIKEL: EFEKTIVITAS TERAPI PENAMBAHAN IVABRADINE UNTUK PASIEN GAGAL JANTUNG DENGAN PENURUNAN FRAKSI EJEKSI (HEART FAILURE REDUCED FRACTION EJECTION)
Abstrak
Abstrak
Gagal jantung adalah masalah kesehatan dengan angka morbiditas dan kematian yang tinggi. Salah satu klasifikasi gagal jantung adalah dengan penurunan fraksi ejeksi (HFrEF) yang memiliki karakteristik nilai LVEF < 40 dan denyut jantung yang sangat tinggi. Pada pasien dengan karakteristik ini, dapat diberikan beta blockers dengan penambahan ivabradine ke dalam regimen terapi untuk mengoptimalkan hasil terapi. Review ini bertujuan untuk menelaah efektivitas penambahan terapi ivabradine ke dalam regimen pengobatan tersebut. Metode yang digunakan adalah penelaahan pustaka dari jurnal yang berkaitan dengan penambahan ivabradine untuk pasien HFrEF. Hasil yang didapatkan yaitu ivabradine dapat digunakan pada pasien HFrEF dengan ritme sinus dan denyut jantung >70 denyut per menit. Ivabradine bersama beta blocker dinilai efektif untuk mengurangi angka rehospitalisasi dan mortalitas akibat kardiovaskuler dan dapat digunakan untuk pasien yang intoleran atau kontraindikasi dengan beta blocker.
ABSTRACT
Heart failure is a health problem with high rates of morbidity and death. One classification of heart failure is with a decrease in ejection fraction (HFrEF) which has the characteristic LVEF value < 40 and a very high heart rate. In patients with this characteristic, beta blockers can be given with the addition of ivabradine into the therapeutic regimen to optimize the results of therapy. An increase in heart rate >70 bpm is an important indicator of mortality, so prompt and cost-effective treatment is needed, such as the addition of ivabradine to standard therapy for HFrEF. This review aims to study the effectiveness of adding ivabradine therapy to the treatment regimen. The method used is a literature study of journals related to the addition of ivabradine to HFrEF patients. The results obtained are that ivabradine can be used in HFrEF patients with sinus rhythm and heart rate >70 bpm. Ivabradine together with beta blockers are considered effective for reducing rehospitalization and mortality rates due to cardiovascular and can be used for patients who are intolerant or contraindicated with beta blockers.
Teks Lengkap:
PDFReferensi
Abi-Samra, F. and Gutterman, D. (2016) ‘Cardiac contractility modulation: a novel approach for the treatment of heart failure’, Heart Failure Reviews, 21(6), pp. 645–660. doi: 10.1007/s10741-016-9571-6.
Adena, M. A., Hamann, G. and Sindone, A. P. (2019) ‘Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure’, Heart Lung and Circulation, 28(3), pp. 414–422. doi: 10.1016/j.hlc.2018.01.011.
Badu-Boateng, C., Jennings, R. and Hammersley, D. (2018) ‘The therapeutic role of ivabradine in heart failure’, Therapeutic Advances in Chronic Disease, 9(11), pp. 199–207. doi: 10.1177/2040622318784556.
Bocchi, E. A. and Salemi, V. M. C. (2019) ‘Ivabradine for treatment of heart failure’, Expert Opinion on Drug Safety, 18(5), pp. 393–402. doi: 10.1080/14740338.2019.1612873.
Bouabdallaoui, N. et al. (2019) ‘Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.’, ESC Heart Failure, 6(6), pp. 1199–1207. doi: 10.1002/ehf2.12513.
Bryan Richard, S. et al. (2021) ‘Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials’, Clinical Cardiology, 44(4), pp. 463–471. doi: 10.1002/clc.23581.
Eid, H. et al. (2020) ‘Evaluation of Clinical outcomes of Generic versus Reference Ivabradine in Heart Failure Patients’, Archives of Pharmaceutical Sciences Ain Shams University, 4(2), pp. 194–206. doi: 10.21608/aps.2020.43341.1041.
Foster, J. L. and Bobadilla, R. V. (2016) ‘Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction’, Journal of the American Association of Nurse Practitioners, 28(11), pp. 576–582. doi: 10.1002/2327-6924.12371.
Griffiths, A. et al. (2014) ‘The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective’, Heart, 100(13), pp. 1031–1036. doi: 10.1136/heartjnl-2013-304598.
Hartmann, C. et al. (2018) ‘The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis’, International Journal of Clinical Pharmacy, 40(6), pp. 1443–1453. doi: 10.1007/s11096-018-0715-8.
Hidalgo, F. J. et al. (2017) ‘Early Therapy with Beta Blockers Plus Ivabradine Versus Beta Blockers Alone in Patients Hospitalised with Heart Failure and Reduced Ejection Fraction (ETHIC-AHF Study): Results at One-Year Follow-Up’, International Journal of Clinical Cardiology, 4(1). doi: 10.23937/2378-2951/1410093.
Kansal, A. R. et al. (2016) ‘Cost-Effectiveness of Ivabradine for Heart Failure in the United States’, Journal of the American Heart Association, 5(5). doi: 10.1161/JAHA.116.003221.
Komajda, M. et al. (2016) ‘Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT’, European Journal of Heart Failure, 18(9), pp. 1182–1189. doi: 10.1002/ejhf.582.
Koruth, J. S. et al. (2017) ‘The Clinical Use of Ivabradine’, Journal of the American College of Cardiology, 70(14), pp. 1777–1784. doi: 10.1016/j.jacc.2017.08.038.
Krittayaphong, R., Yadee, J. and Permsuwan, U. (2019) ‘Cost-effectiveness analysis of the adjunctive therapy of ivabradine for the treatment of heart failure with reduced ejection fraction’, ClinicoEconomics and Outcomes Research, 11, pp. 767–777. doi: 10.2147/CEOR.S226568.
Mizzaci, C., Vilela, A. T. and Riera, R. (2016) ‘Ivabradine as adjuvant treatment for chronic heart failure’, Cochrane Database of Systematic Reviews, 2020(12). doi: 10.1002/14651858.CD010656.pub2.
Müller-Werdan, U., Stöckl, G. and Werdan, K. (2016) ‘Advances in the management of heart failure: The role of ivabradine’, Vascular Health and Risk Management, 12, pp. 453–470. doi: 10.2147/VHRM.S90383.
Nikolovska Vukadinović, A. et al. (2017) ‘Heart rate and its reduction in chronic heart failure and beyond’, European Journal of Heart Failure, 19(10), pp. 1230–1241. doi: 10.1002/ejhf.902.
Oliphant, C. S. et al. (2016) ‘Ivabradine: A Review of Labeled and Off-Label Uses’, American Journal of Cardiovascular Drugs, 16(5), pp. 337–347. doi: 10.1007/s40256-016-0178-z.
Ponikowski, P. et al. (2016) ‘2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure’, European Heart Journal, 37(27), pp. 2129-2200m. doi: 10.1093/eurheartj/ehw128.
Suwandi, J. F., Putri, G. T. and Permatasari, P. I. (2019) ‘Mekanisme Ivabradine sebagai Terapi Gagal Jantung dengan Penurunan Fraksi Ejeksi Mechanism of Ivabradine as Heart Failure-Reduced-Ejection Fraction Therapy’, 3, pp. 198–204.
Thorup, L. et al. (2017) ‘Ivabradine: Current and Future Treatment of Heart Failure’, Basic and Clinical Pharmacology and Toxicology, 121(2), pp. 89–97. doi: 10.1111/bcpt.12784.
Tondi, L. et al. (2018) ‘Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure’, Journal of Cardiovascular Medicine, 19(7), pp. 351–356. doi: 10.2459/JCM.0000000000000661.
Tsutsui, H. et al. (2019) ‘Efficacy and safety of ivabradine in Japanese patients with chronic heart failure ― J-SHIFT study ―’, Circulation Journal, 83(10), pp. 2049–2060. doi: 10.1253/circj.CJ-19-0227.
Weeda, E. R., Nguyen, E. and White, C. M. (2016) ‘Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease’, Annals of Pharmacotherapy, 50(6), pp. 475–485. doi: 10.1177/1060028016631571.
DOI: https://doi.org/10.24198/farmaka.v20i1.33905
DOI (PDF): https://doi.org/10.24198/farmaka.v20i1.33905.g17345
Refbacks
- Saat ini tidak ada refbacks.
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved